Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Rabies Clinical Trial

Official title:
A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects

Status Completed

Clinical Trial Summary

Study design:

Single-blind (subject and observer-blinded), active-controlled, randomized [6:2:1:2:1; CL184 + purified vero cell rabies vaccine (PVRV) vs. human rabies immune globulin (HRIG) + PVRV vs. placebo + PVRV vs. CL184 + human diploid cell vaccine (HDCV) vs. placebo + HDCV], mono-center study

Study objectives:

Primary: To evaluate the safety of CL184 in combination with PVRV in healthy adult subjects.

Secondary: To evaluate the safety of HRIG or placebo in combination with PVRV and to evaluate the safety of CL184 or placebo in combination with HDCV in healthy adult subjects. To evaluate the rabies virus neutralizing activity (RVNA) after administration of CL184 or placebo in combination with PVRV, of HRIG in combination with PVRV, and of CL184 or placebo in combination with HDCV in healthy adult subjects. To evaluate the pharmacokinetics of the monoclonal antibodies (mAbs).

Clinical Trial Description

This study was designed to explore and obtain further safety and RVNA data on CL184 in comparison to HRIG and placebo as part of a classical post-exposure prophylaxis (PEP) regimen. This regimen will be applied as simulated PEP regimen to healthy subjects (i.e. in a pre-exposure setting) in this study. A comparison with placebo combined with each rabies vaccine was included to differentiate between the contribution of immune globulin and vaccine and to investigate potential interactions between immune globulin and vaccine. RVNA provided by CL184 or HRIG, as well as vaccination response will be checked regularly during the study and booster doses can be applied after the study, if necessary. In addition pharmacokinetic data will be collected. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Rabies

Clinical Trial Details

NCT number	NCT01228383
Study type	Interventional
Source	Crucell Holland BV
Contact
Status	Completed
Phase	Phase 2
Start date	December 2011
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03961555` - Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies	Phase 2
Completed	`NCT04644484` - A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety	Phase 3
Active, not recruiting	`NCT05667974` - A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried	Phase 3
Completed	`NCT01641315` - Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins	N/A
Completed	`NCT02238756` - Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults	Phase 1
Completed	`NCT01930357` - Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen	Phase 2
Completed	`NCT01680016` - A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults	Phase 3
Completed	`NCT04019444` - Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects	Phase 1
Completed	`NCT02729168` - Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly	N/A
Completed	`NCT02241135` - RNActive® Rabies Vaccine (CV7201) in Healthy Adults	Phase 1
Completed	`NCT01388985` - Simplifying the Rabies Pre-exposure Vaccination	Phase 3
Completed	`NCT04829630` - Immunity Persistence After Abridged Intradermal Rabies PEP	N/A
Completed	`NCT03713086` - A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults	Phase 1
Completed	`NCT05350735` - Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project	N/A
Active, not recruiting	`NCT06132789` - A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Years	Phase 1
Completed	`NCT02281396` - The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans	Phase 1
Completed	`NCT01466387` - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Phase 3
Completed	`NCT00825305` - Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)	Phase 3
Completed	`NCT05547815` - Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine	Phase 4
Completed	`NCT02564471` - Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.	Phase 4